Last reviewed · How we verify
Liposomal paclitaxel and capecitabine — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Liposomal paclitaxel and capecitabine (Liposomal paclitaxel and capecitabine) — Nanjing Sike Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Liposomal paclitaxel and capecitabine TARGET | Liposomal paclitaxel and capecitabine | Nanjing Sike Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Liposomal paclitaxel and capecitabine CI watch — RSS
- Liposomal paclitaxel and capecitabine CI watch — Atom
- Liposomal paclitaxel and capecitabine CI watch — JSON
- Liposomal paclitaxel and capecitabine alone — RSS
Cite this brief
Drug Landscape (2026). Liposomal paclitaxel and capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/liposomal-paclitaxel-and-capecitabine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab